These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36366355)

  • 41. Mathematical analysis of the transmission dynamics of COVID-19 infection in the presence of intervention strategies.
    Teklu SW
    J Biol Dyn; 2022 Dec; 16(1):640-664. PubMed ID: 35972455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modelling the effects of media coverage and quarantine on the COVID-19 infections in the UK.
    Feng LX; Jing SL; Hu SK; Wang DF; Huo HF
    Math Biosci Eng; 2020 May; 17(4):3618-3636. PubMed ID: 32987547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mathematical modeling and optimal control of SARS-CoV-2 and tuberculosis co-infection: a case study of Indonesia.
    Rwezaura H; Diagne ML; Omame A; de Espindola AL; Tchuenche JM
    Model Earth Syst Environ; 2022; 8(4):5493-5520. PubMed ID: 35814616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complex dynamics and control analysis of an epidemic model with non-monotone incidence and saturated treatment.
    Saha P; Ghosh U
    Int J Dyn Control; 2023; 11(1):301-323. PubMed ID: 35637768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Backward bifurcation and control in transmission dynamics of arboviral diseases.
    Abboubakar H; Claude Kamgang J; Tieudjo D
    Math Biosci; 2016 Aug; 278():100-29. PubMed ID: 27321192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How do the contaminated environment influence the transmission dynamics of COVID-19 pandemic?
    Sarkar K; Mondal J; Khajanchi S
    Eur Phys J Spec Top; 2022; 231(18-20):3697-3716. PubMed ID: 36033354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
    Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
    Front Immunol; 2022; 13():888248. PubMed ID: 35844604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamics of a malaria infection model with time delay.
    Ding Q; Liu J; Guo ZM
    Math Biosci Eng; 2019 May; 16(5):4885-4907. PubMed ID: 31499695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling the transmission dynamics of middle eastern respiratory syndrome coronavirus with the impact of media coverage.
    Fatima B; Alqudah MA; Zaman G; Jarad F; Abdeljawad T
    Results Phys; 2021 May; 24():104053. PubMed ID: 33777666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
    Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
    Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A mathematical model to study the COVID-19 pandemic in India.
    Tripathi A; Tripathi RN; Sharma D
    Model Earth Syst Environ; 2022; 8(3):3047-3058. PubMed ID: 34580646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study.
    Molodtsov IA; Kegeles E; Mitin AN; Mityaeva O; Musatova OE; Panova AE; Pashenkov MV; Peshkova IO; Alsalloum A; Asaad W; Budikhina AS; Deryabin AS; Dolzhikova IV; Filimonova IN; Gracheva AN; Ivanova OI; Kizilova A; Komogorova VV; Komova A; Kompantseva NI; Kucheryavykh E; Lagutkin DА; Lomakin YA; Maleeva AV; Maryukhnich EV; Mohammad A; Murugin VV; Murugina NE; Navoikova A; Nikonova MF; Ovchinnikova LA; Panarina Y; Pinegina NV; Potashnikova DM; Romanova EV; Saidova AA; Sakr N; Samoilova AG; Serdyuk Y; Shakirova NT; Sharova NI; Sheetikov SA; Shemetova AF; Shevkova LV; Shpektor AV; Trufanova A; Tvorogova AV; Ukrainskaya VM; Vinokurov AS; Vorobyeva DA; Zornikova KV; Efimov GA; Khaitov MR; Kofiadi IA; Komissarov AA; Logunov DY; Naigovzina NB; Rubtsov YP; Vasilyeva IA; Volchkov P; Vasilieva E
    Clin Infect Dis; 2022 Aug; 75(1):e1-e9. PubMed ID: 35435222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CCR2 Signaling Restricts SARS-CoV-2 Infection.
    Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
    mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bifurcation analysis of a network-based SIR epidemic model with saturated treatment function.
    Li CH; Yousef AM
    Chaos; 2019 Mar; 29(3):033129. PubMed ID: 30927836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: a systematic review of evidence to support global policy-level actions and research.
    Nair S; Chen X
    Glob Health J; 2022 Mar; 6(1):38-43. PubMed ID: 34840854
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].
    Erensoy S
    Mikrobiyol Bul; 2020 Jul; 54(3):497-509. PubMed ID: 32755524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.